Literature DB >> 9699763

Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin.

M D Pearlman1, C L Pierson, R G Faix.   

Abstract

OBJECTIVE: To determine both the frequency of reported penicillin allergy in parturients and the frequency of resistance in vitro of clinical isolates of group B streptococci to clindamycin and erythromycin.
METHODS: One hundred clinical isolates of group B streptococci were tested to determine the frequency of resistance to clindamycin, erythromycin, penicillin G, vancomycin, and cefazolin. The frequency of beta-lactam allergy and reported allergic reaction also were recorded for all consecutive laboring women during the 4-month study.
RESULTS: The frequency of group B streptococcal resistance to clindamycin was 15% and to erythromycin was 16%. No isolates were resistant to penicillin G, vancomycin, or cefazolin. Twelve percent of the 963 women who delivered during the study reported a penicillin allergy, but only 30% of those could describe their allergic reaction.
CONCLUSION: In vitro resistance of group B streptococci to clindamycin and erythromycin occurred frequently in this population. Whereas the importance of this finding in vivo is uncertain, it raises concern about the possibility of inadequate prophylaxis using currently recommended alternatives in penicillin-allergic patients. Artful questioning of women reporting penicillin allergy may lessen the likelihood of using these less desirable agents in the setting of intrapartum antimicrobial prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699763     DOI: 10.1016/s0029-7844(98)00155-0

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  30 in total

1.  Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study.

Authors:  D De Mouy; J D Cavallo; R Leclercq; R Fabre
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; S W Ho; P C Yang; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Prevention of group B streptococcal infection in newborns: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

4.  Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.

Authors:  Daniel J Diekema; Janet I Andrews; Holly Huynh; Paul R Rhomberg; Stella R Doktor; Jill Beyer; Virginia D Shortridge; Robert K Flamm; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

5.  Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.

Authors:  F Fitoussi; C Loukil; I Gros; O Clermont; P Mariani; S Bonacorsi; I Le Thomas; D Deforche; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  Prevention of group B streptococcal infection in newborns. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

7.  A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany.

Authors:  Ulrich von Both; Michael Ruess; Urban Mueller; Kirsten Fluegge; Anna Sander; Reinhard Berner
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  Antimicrobial susceptibilities of group B streptococci in New Zealand.

Authors:  Anja M Werno; Trevor P Anderson; David R Murdoch
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Heterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates.

Authors:  Ulrich von Both; Anna Buerckstuemmer; Kirsten Fluegge; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

10.  Erythromycin and clindamycin resistance in group B streptococcal clinical isolates.

Authors:  Scott E Gygax; Jessica A Schuyler; Lauren E Kimmel; Jason P Trama; Eli Mordechai; Martin E Adelson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.